HS#:

Title:

LR Name:

Appendix N

COLLECTION OF GENETIC SPECIMENS AND GENETIC TESTING STUDIES

University of California, Irvine

Institutional Review Board

This appendix must be completed for studies that involve the collection of specimens for genetic research and/or testing. This includes any studies involving the study of the genetic mechanisms of human disease and health. Genetic specimens include blood, saliva, solid tumors, and any other tissues or body fluids used for genetic testing.

The IRB is responsible for reviewing genetic testing to protect the privacy of subjects by ensuring that appropriate mechanisms are in place to assure the confidentiality of the specimens and testing results. Some testing results could have the potential to define genetic traits or mechanisms belonging to an individual or population that have the potential to cause harm to study subjects.

Note: If your study involves storage of genetic specimens (including specimens that are sent to a repository), Appendix M is also required.

1.Specify the type of specimens collected:

2.Specify the type of genetic testing to be performed (check all that apply):

Somatic or Non-Diagnostic Genetics

DNA sequence data will be generated that is not clearly diagnostic (i.e., it provides no additional clinical information about the subject) and will not be relevant to the subject’s future health or other family members beyond study participation.

Examples include: sequencing subject tumor DNA to detect acquired mutations or detection of germ line DNA polymorphisms of undefined clinical significance.

Gene Expression, Biochemical or Qualitative

No direct DNA sequence data will be generated. Data is only relevant to the patient’s currently diagnosed state of health. Examples include immunohistochemical analysis (staining tissues to detect proteins), serum biomarker studies, and gene expression analysis.

Pharmacogenetic

Data relates a specific genotype to a drug response to determine who may obtain the greatest potential benefit from a particular drug and those individuals who may be at the greatest risk of side effects from a particular drug.

Germ Line Genetics of Complex Disease

A complex disease is defined by multiple inherited (genetic) and environmental risk factors, none of which on their own are either necessary or sufficient to cause disease.

Examples include: DNA sequencing of a defined locus that may have a suspected (but unproven) involvement in predisposing the subject to a defined phenotype.

Germ Line or Diagnostic Genetics of Mendelian Disorders

A Mendelian disorder is defined by the presence of one or two disease alleles at a single locus, signifying that the subject and/or family members will develop the disorder. DNA sequence or other genetic data will be generated that could be directly relevant to the subject’s future health and/or the subject’s family.

Examples include: DNA sequencing to predict relative risk of disease or to identify heritable traits.

3.Indicate the type of subject identifiers that will be attached to the data/specimens:

Specimens will be stripped of all direct and indirect identifiers and cannot be linked to the subjects (anonymous specimens).

Specimens will be linked to the subjects with direct identifiers.

Specimens will be linked to the subjects with indirect identifiers (coded specimens)

  1. Will a CLIA approved lab be used to process/analyze the specimens?

Note: if a CLIA approved lab is not being used the test results cannot be used for medical treatment. See for more information about CLIA

YesNo

5.Will pedigree analysis and/or family linkage studies be performed?

Note: subjects must be informed that the study may determine that some members of their family are not genetic relatives and that other family members may learn private genetic information about them (as applicable to the study). Strict confidentiality must be maintained for each individual subject.

Yes No

6.Will subjects be informed of the results of genetic testing?

Yes –Subjects will be notified of their testing results

No - Subjects will not be notified of their testing results

7.Will the results of genetic testing become a part of the subjects’ medical record?

Yes –Genetic testing information will become part of the subjects’ medical record.

No – Genetic testing information will not become part of the subjects’ medical record.